ID   TP2B_HUMAN     STANDARD;      PRT;  1626 AA.
AC   Q02880; Q9UQP8; Q13600; Q9UMG8;
DT   01-JUL-1993 (Rel. 26, Created)
DT   01-MAR-2002 (Rel. 41, Last sequence update)
DT   01-MAR-2002 (Rel. 41, Last annotation update)
DE   DNA topoisomerase II, beta isozyme (EC 5.99.1.3).
GN   TOP2B.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=93087165; PubMed=1333583;
RA   Jenkins J.R., Ayton P., Jones T., Davies S.L., Simmons D.L.,
RA   Harris A.L., Sheer D., Hickson I.D.;
RT   "Isolation of cDNA clones encoding the beta isozyme of human DNA
RT   topoisomerase II and localisation of the gene to chromosome 3p24.";
RL   Nucleic Acids Res. 20:5587-5592(1992).
RN   [2]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=93192319; PubMed=8383537;
RA   Austin C.A., Sng J.H., Patel S., Fisher L.M.;
RT   "Novel HeLa topoisomerase II is the II beta isoform: complete coding
RT   sequence and homology with other type II topoisomerases.";
RL   Biochim. Biophys. Acta 1172:283-291(1993).
RN   [3]
RP   SEQUENCE OF 149-1034 FROM N.A.
RX   MEDLINE=90083281; PubMed=2556712;
RA   Chung T.D., Drake F.H., Tan K.B., Per S.R., Crooke S.T.,
RA   Mirabelli C.K.;
RT   "Characterization and immunological identification of cDNA clones
RT   encoding two human DNA topoisomerase II isozymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9431-9435(1989).
RN   [4]
RP   SEQUENCE OF 910-1626 FROM N.A.
RX   MEDLINE=99196712; PubMed=10095062;
RA   Sng J.H., Heaton V.J., Bell M., Mani P., Austin C.A., Fisher L.M.;
RT   "Molecular cloning and characterization of the human topoisomerase
RT   IIalpha and IIbeta genes: evidence for isoform evolution through gene
RT   duplication.";
RL   Biochim. Biophys. Acta 1444:395-406(1999).
RN   [5]
RP   SEQUENCE OF 1038-1271 FROM N.A.
RX   MEDLINE=90306333; PubMed=2163884;
RA   Austin C.A., Fisher L.M.;
RT   "Isolation and characterization of a human cDNA clone encoding a
RT   novel DNA topoisomerase II homologue from HeLa cells.";
RL   FEBS Lett. 266:115-117(1990).
RN   [6]
RP   SEQUENCE OF 1277-1626 FROM N.A.
RA   Yuwen H.;
RT   "Binding of wild-type p53 by topoisomerase II and overexpression of
RT   topoisomerase II in human hepatocellular carcinoma.";
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   ALTERNATIVE SPLICING.
RX   MEDLINE=93376494; PubMed=8396237;
RA   Davies S.L., Jenkins J.R., Hickson I.D.;
RT   "Human cells express two differentially spliced forms of
RT   topoisomerase II beta mRNA.";
RL   Nucleic Acids Res. 21:3719-3723(1993).
CC   -!- FUNCTION: CONTROL OF TOPOLOGICAL STATES OF DNA BY TRANSIENT
CC       BREAKAGE AND SUBSEQUENT REJOINING OF DNA STRANDS. TOPOISOMERASE II
CC       MAKES DOUBLE-STRAND BREAKS.
CC   -!- CATALYTIC ACTIVITY: ATP-dependent breakage, passage and rejoining
CC       of double-stranded DNA.
CC   -!- SUBUNIT: HOMODIMER.
CC   -!- SUBCELLULAR LOCATION: NUCLEAR; NUCLEOLUS.
CC   -!- ALTERNATIVE PRODUCTS: 2 ISOFORMS; BETA-1 AND BETA-2 (SHOWN HERE);
CC       ARE PRODUCED BY ALTERNATIVE SPLICING.
CC   -!- PTM: PHOSPHORYLATED.
CC   -!- MISCELLANEOUS: EUKARYOTIC TOPOISOMERASE I AND II CAN RELAX BOTH
CC       NEGATIVE AND POSITIVE SUPERCOILS, WHEREAS PROKARYOTIC ENZYMES
CC       RELAX ONLY NEGATIVE SUPERCOILS.
CC   -!- SIMILARITY: BELONGS TO THE TYPE II TOPOISOMERASE FAMILY.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X68060; CAA48197.1; -.
DR   EMBL; X71911; -; NOT_ANNOTATED_CDS.
DR   EMBL; Z15111; CAA78815.1; -.
DR   EMBL; Z15115; CAA78821.1; -.
DR   EMBL; M27504; AAA61210.1; -.
DR   EMBL; AJ011721; CAA09753.1; -.
DR   EMBL; AJ011722; CAA09753.1; JOINED.
DR   EMBL; AJ011723; CAA09753.1; JOINED.
DR   EMBL; AJ011724; CAA09753.1; JOINED.
DR   EMBL; AJ011725; CAA09753.1; JOINED.
DR   EMBL; AJ011726; CAA09753.1; JOINED.
DR   EMBL; AJ011727; CAA09753.1; JOINED.
DR   EMBL; AJ011728; CAA09753.1; JOINED.
DR   EMBL; AJ011729; CAA09753.1; JOINED.
DR   EMBL; AJ011730; CAA09753.1; JOINED.
DR   EMBL; AJ011731; CAA09753.1; JOINED.
DR   EMBL; AJ011732; CAA09753.1; JOINED.
DR   EMBL; X53662; CAA37706.1; -.
DR   EMBL; U54831; AAB01982.1; -.
DR   PIR; S26730; S26730.
DR   PIR; S10710; S10710.
DR   PIR; S41641; S41641.
DR   HSSP; P06786; 1BGW.
DR   MIM; 126431; -.
DR   InterPro; IPR003957; CBFA_NFYB_topis.
DR   InterPro; IPR001241; DNA_topoisoII.
DR   InterPro; IPR002205; DNA_topoisoIV.
DR   InterPro; IPR003594; HATPase_c.
DR   Pfam; PF00204; DNA_gyraseB; 1.
DR   Pfam; PF00521; DNA_topoisoIV; 1.
DR   Pfam; PF02518; HATPase_c; 1.
DR   PRINTS; PR00615; CCAATSUBUNTA.
DR   PRINTS; PR00418; TPI2FAMILY.
DR   ProDom; PD000742; DNA_topoisoIV; 1.
DR   SMART; SM00433; TOP2c; 1.
DR   SMART; SM00434; TOP4c; 1.
DR   PROSITE; PS00177; TOPOISOMERASE_II; 1.
KW   Isomerase; Topoisomerase; DNA-binding; ATP-binding; Phosphorylation;
KW   Alternative splicing; Nuclear protein.
FT   NP_BIND     182    187       ATP (POTENTIAL).
FT   ACT_SITE    826    826       DNA CLEAVAGE (BY SIMILARITY).
FT   VARSPLIC     24     28       MISSING (IN ISOFORM BETA-1).
FT   CONFLICT   1431   1431       T -> S (IN REF. 4).
FT   CONFLICT   1611   1611       A -> T (IN REF. 1).
FT   CONFLICT   1621   1621       D -> H (IN REF. 4).
SQ   SEQUENCE   1626 AA;  183266 MW;  E60E9262CC68B05D CRC64;
     MAKSGGCGAG AGVGGGNGAL TWVTLFDQNN AAKKEESETA NKNDSSKKLS VERVYQKKTQ
     LEHILLRPDT YIGSVEPLTQ FMWVYDEDVG MNCREVTFVP GLYKIFDEIL VNAADNKQRD
     KNMTCIKVSI DPESNIISIW NNGKGIPVVE HKVEKVYVPA LIFGQLLTSS NYDDDEKKVT
     GGRNGYGAKL CNIFSTKFTV ETACKEYKHS FKQTWMNNMM KTSEAKIKHF DGEDYTCITF
     QPDLSKFKME KLDKDIVALM TRRAYDLAGS CRGVKVMFNG KKLPVNGFRS YVDLYVKDKL
     DETGVALKVI HELANERWDV CLTLSEKGFQ QISFVNSIAT TKGGRHVDYV VDQVVGKLIE
     VVKKKNKAGV SVKPFQVKNH IWVFINCLIE NPTFDSQTKE NMTLQPKSFG SKCQLSEKFF
     KAASNCGIVE SILNWVKFKA QTQLNKKCSS VKYSKIKGIP KLDDANDAGG KHSLECTLIL
     TEGDSAKSLA VSGLGVIGRD RYGVFPLRGK ILNVREASHK QIMENAEINN IIKIVGLQYK
     KSYDDAESLK TLRYGKIMIM TDQDQDGSHI KGLLINFIHH NWPSLLKHGF LEEFITPIVK
     ASKNKQELSF YSIPEFDEWK KHIENQKAWK IKYYKGLGTS TAKEAKEYFA DMERHRILFR
     YAGPEDDAAI TLAFSKKKID DRKEWLTNFM EDRRQRRLHG LPEQFLYGTA TKHLTYNDFI
     NKELILFSNS DNERSIPSLV DGFKPGQRKV LFTCFKRNDK REVKVAQLAG SVAEMSAYHH
     GEQALMMTIV NLAQNFVGSN NINLLQPIGQ FGTRLHGGKD AASPRYIFTM LSTLARLLFP
     AVDDNLLKFL YDDNQRVEPE WYIPIIPMVL INGAEGIGTG WACKLPNYDA REIVNNVRRM
     LDGLDPHPML PNYKNFKGTI QELGQNQYAV SGEIFVVDRN TVEITELPVR TWTQVYKEQV
     LEPMLNGTDK TPALISDYKE YHTDTTVKFV VKMTEEKLAQ AEAAGLHKVF KLQTTLTCNS
     MVLFDHMGCL KKYETVQDIL KEFFDLRLSY YGLRKEWLVG MLGAESTKLN NQARFILEKI
     QGKITIENRS KKDLIQMLVQ RGYESDPVKA WKEAQEKAAE EDETQNQHDD SSSDSGTPSG
     PDFNYILNMS LWSLTKEKVE ELIKQRDAKG REVNDLKRKS PSDLWKEDLA AFVEELDKVE
     SQEREDVLAG MSGKAIKGKV GKPKVKKLQL EETMPSPYGR RIIPEITAMK ADASKKLLKK
     KKGDLDTAAV KVEFDEEFSG APVEGAGEEA LTPSVPINKG PKPKREKKEP GTRVRKTPTS
     SGKPSAKKVK KRNPWSDDES KSESDLEETE PVVIPRDSLL RRAAAERPKY TFDFSEEEDD
     DADDDDDDNN DLEELKVKAS PITNDGEDEF VPSDGLDKDE YTFSPGKSKA TPEKSLHDKK
     SQDFGNLFSF PSYSQKSEDD SAKFDSNEED SASVFSPSFG LKQTDKVPSK TVAAKKGKPS
     SDTVPKPKRA PKQKKVVEAV NSDSDSEFGI PKKTTTPKGK GRGAKKRKAS GSENEGDYNP
     GRKTSKTTSK KPKKTSFDQD SDVDIFPSDF PTEPPSLPRT GRARKEVKYF AESDEEEDDV
     DFAMFN
//